^
    CanScan™ utilizes low-depth whole-genome sequencing (WGS) on circulating cell-free DNA (cfDNA) from a single tube of peripheral blood, extracting genetic and fragmentomic features to detect early cancer signals with 99% specificity and predict the tissue of origin (TOO) of cancers to help guide next steps for cancer diagnosis. CanScan™ exhibits promising potential to address unmet medical needs in clinical diagnosis and treatment, particularly for individuals aged 50 and above with an average risk of cancer. Built on Geneseeq’s highly sensitive MERCURY™ multi-omics technology, the performance of CanScan™ has been validated in large-scale clinical study series.
    Cancer:
    Endometrial Cancer, Esophageal Cancer, Gastric Cancer, Liver Cancer, Lung Cancer, Lymphoma, Pancreatic Cancer, Prostate Cancer
    Method:
    Whole-genome sequencing (WGS)
    Approvals
    Date
    Cancer
    Gene
    Drug
    By
    01/24/23
    ST
    -
    CE